[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-360029-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-360029-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","immune-checkpoint-blockade-and-emerging-combination-platforms-in-breast-cancer-a-narrative-review","Immune Checkpoint Blockade and Emerging Combination Platforms in Breast Cancer - A Narrative Review","","This narrative review examines recent progress in immunotherapy for breast cancer, emphasizing immune checkpoint inhibitors used alone and in combination with other modalities. It highlights landmark trials such as KEYNOTE-522 and IMpassion130 supporting pembrolizumab and atezolizumab in triple-negative breast cancer, while noting ongoing mortality burden. Combination strategies are organized into mechanisms that remodel the immunosuppressive tumor microenvironment, enhance effector cell persistence, and target additional immune checkpoint axes beyond PD-1/CTLA-4.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/immune-checkpoint-blockade-and-emerging-combination-platforms-in-breast-cancer-a-narrative-review/360029/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/immune-checkpoint-blockade-and-emerging-combination-platforms-in-breast-cancer-a-narrative-review/360029.png","ImageObject",300,407,{"name":42,"@type":43},"Bintang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main focus of this narrative review on breast cancer immunotherapy?","Question",{"text":63,"@type":64},"It reviews progress in immunotherapy for breast cancer, concentrating on immune checkpoint inhibitors alone and combined with other treatment modalities.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which landmark trials are mentioned as evidence for certain therapies in triple-negative breast cancer?",{"text":68,"@type":64},"The review cites KEYNOTE-522 and IMpassion130 as landmark trials supporting pembrolizumab and atezolizumab in triple-negative breast cancer.",{"name":70,"@type":61,"acceptedAnswer":71},"How are combination strategies grouped in the review?",{"text":72,"@type":64},"They are synthesized into three mechanistic categories: remodeling the immunosuppressive tumor microenvironment, enhancing effector cell persistence, and modulating immune checkpoint axes beyond PD-1/CTLA-4.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},360029,1790197090,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Breast Cancer: Targets and Therapy  \nOpen Access Full Text Article REVIEW  \nImmune Checkpoint Blockade and Emerging Combination Platforms in Breast Cancer:  \nA Narrative Review  \nMaryam Abbaspour 1 , Nafiseh Esmaeil 2 , Vajihe Akbari 1 , Mohammad Ghoreishi 1 , Haniyeh Rafiepoor 3  \n1Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran; 2Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; 3Cancer Biology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran  \nCorrespondence: Nafiseh Esmaeil, Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, 81744-176, Iran, Tel +98 31 37929097, Fax +98 3113 7929031, Email [n_esmaeil@med.mui.ac.ir](n_esmaeil@med.mui.ac.ir)  \n\n| Abstract: This narrative review examines recent progress in immunotherapy for breast cancer (BC), focusing on immune checkpoint inhibitors (ICIs) alone and in combination with other modalities. Landmark trials such as KEYNOTE-522 and IMpassion130 have established the efficacy of pembrolizumab and atezolizumab in triple-negative breast cancer (TNBC) . However, BC remains a leading cause of cancer-related fatalities, underscoring the need for novel approaches. We synthesize combination strategies into three mechanistic categories: (I) those that remodel the immunosuppressive tumor microenvironment (chemotherapy, PARP inhibitors, oncolytic viruses); (II) those that enhance effector cell persistence (CAR-T, CAR-NK, cytokine support); and (III) those that modulate immune checkpoint axes beyond PD-1/CTLA-4 (LAG-3, TIM-3, TIGIT) . Combining ICIs with CAR-T cells, CAR-NK cells, oncolytic viruses, and exosomes has been shown to improve antitumor immune responses. This review provides a translational framework for biomarker-driven patient stratification and critically evaluates the clinical maturity of emerging platforms. Further research and clinical trials are needed to expand applicability across BC subtypes and improve patient outcomes.\u003Cbr>Keywords: breast cancer, immunotherapy, checkpoint inhibitors, CAR T cells, CAR NK cells, oncolytic viruses, exosomes |\n| --- |\n| Introduction\u003Cbr>Despite ongoing progress in medicine, breast cancer (BC) remains the second most common and deadly cancer among women. In the United States, over 270,000 women are diagnosed each year with invasive BC.1 The rates of diagnosis and death vary by region due to differences in socioeconomic, environmental, and healthcare factors.2\u003Cbr>BC is categorized by the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), which are important for prognosis and treatment. Most breast carcinomas are ER-positive; among these, more than half also express PR, while only about 2% are exclusively PR-positive. HER2-positive tumors are aggressive but respond to targeted therapies. In contrast, triple-negative breast cancers (TNBC), which lack ER, PR, and HER2, have limited treatment options and a poorer prognosis.2–4\u003Cbr>Recent studies have shown that the immune system plays a significant role in BC, especially regarding the presence of tumor-infiltrating lymphocytes (TILs) . These immune cells are more common in HER2-positive and TNBC subtypes than in hormone receptor-positive tumors.5\u003Cbr>The tumor microenvironment (TME) in BC shows immunosuppressive features. These include the expression of immune checkpoints, immune cell exhaustion, an increase in regulatory immune cells, and the buildup of immunosuppressive metabolites. BC subtypes vary in their immune cell infiltration levels: TNBC and HER2-positive tumors generally have higher levels of infiltration, which is linked to better survival rates. In contrast, ER-positive tumors have lower immune infiltration and worse outcomes.6 Regional lymph nodes from BC patients contain exhausted cytotoxic T cells that express |\n\n[htt","cbCailOklpzT2JIS","https://ap.wps.com/l/cbCailOklpzT2JIS","pdf",2752604,27,"English","# Abstract\n# Introduction","[{\"question\":\"What is the main focus of this narrative review on breast cancer immunotherapy?\",\"answer\":\"It reviews progress in immunotherapy for breast cancer, concentrating on immune checkpoint inhibitors alone and combined with other treatment modalities.\"},{\"question\":\"Which landmark trials are mentioned as evidence for certain therapies in triple-negative breast cancer?\",\"answer\":\"The review cites KEYNOTE-522 and IMpassion130 as landmark trials supporting pembrolizumab and atezolizumab in triple-negative breast cancer.\"},{\"question\":\"How are combination strategies grouped in the review?\",\"answer\":\"They are synthesized into three mechanistic categories: remodeling the immunosuppressive tumor microenvironment, enhancing effector cell persistence, and modulating immune checkpoint axes beyond PD-1/CTLA-4.\"}]","Immune Checkpoint Blockade and Emerging Combination Platforms in Breast Cancer - A Narrative Review | PDF",1790138542,68,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e4ebedbab0847b6c4424fccf71e1128.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd3f4abc4bb4fb057341396b811852d3.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78775dda4f5fe8c2a6d3000aa1a1672f.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f6d6cc988fb97d7c7f0492dfb073e90.webp",980,1268]